Protocol for stage 2 of the GaP study (genetic testing acceptability for Paget's disease of bone): A questionnaire study to investigate whether relatives of people with Paget's disease would accept genetic testing and preventive treatment if they were available

BMC Health Services Research

Volumn 8, Issue , 2008, Pages

  Langston, Anne L ^a   Johnston, Marie ^b   Francis, Jill ^b   Robertson, Clare ^b   Campbell, Marion K ^b   Entwistle, Vikki A ^c   Marteau, Theresa ^d   MacLennan, Graeme ^b   Weinman, John ^e   McCallum, Marilyn ^f   Miedzybrodska, Zosia ^g   Charnock, Keith ^f   Ralston, Stuart H ^h  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f National Association for the Relief of Paget's Disease   (United Kingdom)

^g NHS GRAMPIAN   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; FAMILY HISTORY; GENETIC ANALYSIS; HUMAN; PAGET BONE DISEASE; PATIENT ATTITUDE; PATIENT PARTICIPATION; POSTAL MAIL; PROPHYLAXIS; QUESTIONNAIRE; RELATIVE; THEORY OF PLANNED BEHAVIOR; FAMILY; FEMALE; GENETIC SCREENING; GENETICS; HEALTH BEHAVIOR; MALE; PAGET NIPPLE DISEASE; PSYCHOLOGICAL ASPECT;

FAMILY; FEMALE; GENETIC SCREENING; HEALTH BEHAVIOR; HUMANS; MALE; PAGET'S DISEASE, MAMMARY; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES;

EID: 46149100042     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-8-116     Document Type: Article

References (47)

1. Incidence and natural history of Paget's disease of bone in England and Wales. TP van Staa P Selby HG Leufkens K Lyles JM Sprafka C Cooper, J Bone Miner Res 2002 17 465 471 10.1359/jbmr.2002.17.3.465 11878305
2. Paget's disease of bone and quality of life. DT Gold J Boisture KM Shipp CF Pieper KW Lyles, J Bone Miner Res 1996 11 1897 1904 8970891
3. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. L Hocking F Slee SI Haslam T Cundy G Nicholson W van Hul SH Ralston, Bone 2000 26 577 580 10.1016/S8756-3282(00)00278-7 10831928
4. Frequency and characteristics of familial aggregation of Paget's disease of bone. AA Morales-Piga JS Rey-Rey J Corres-Gonzalez JM Garcia-Sagredo G Lopez-Abente, J Bone Miner Res 1995 10 663 670 7610939
5. Familial aggregation of Paget's disease of bone. ES Siris R Ottman E Flaster JL Kelsey, J Bone Miner Res 1991 6 495 500 2068956
6. Genetics of Paget's disease of bone. A Daroszewska SH Ralston, Clin Sci (Lond) 2005 109 257 263 16104845
7. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. LJ Hocking GJ Lucas A Daroszewska T Cundy GC Nicholson J Donath JP Walsh C Finlayson JR Cavey B Ciani, J Bone Miner Res 2004 19 1122 1127 10.1359/JBMR.0403015 15176995
8. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. LJ Hocking GJ Lucas A Daroszewska J Mangion M Olavesen T Cundy GC Nicholson L Ward ST Bennett W Wuyts, Hum Mol Genet 2002 11 2735 2739 10.1093/hmg/11.22.2735 12374763
9. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. N Laurin JP Brown J Morisette V Raymond, Am J Hum Genet 2002 70 1582 1588 11992264 10.1086/340731
10. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. JR Cavey SH Ralston PW Sheppard B Ciani TR Gallagher JE Long MS Searle R Layfield, Calcif Tissue Int 2006 78 271 277 10.1007/s00223-005-1299-6 16691492
11. Paget's disease of bone. GD Roodman JJ Windle, Journal of Clinical Investigation 2005 115 200 208 15690073
12. The Pro and Con of Measles Virus in Paget's Disease: Pro. WE Friedrichs SV Reddy FJ Singer GD Roodman, Journal of Bone and Mineral Research 2002 17 2293 10.1359/jbmr.2002.17.12.2293
13. The pro and con of measles virus in Paget's disease: con. BK Rima U Gassen MH Helfrich SH Ralston, J Bone Miner Res 2002 17 2290 2292 author reply 2293 10.1359/jbmr.2002.17.12.2290 12469924
14. Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. EW Eekhoff M Karperien D Houtsma AH Zwinderman C Dragoiescu AL Kneppers SE Papapoulos, Arthritis Rheum 2004 50 1650 1654 10.1002/art.20224 15146436
15. Two novel mutations at exon 8 of the Sequestosome 1 (SQSTM1) gene in an Italian series of patients affected by Paget's disease of bone (PDB). A Falchetti M Di Stefano F Marini F Del Monte C Mavilia D Strigoli ML De Feo G Isaia L Masi A Amedei, J Bone Miner Res 2004 19 1013 1017 10.1359/JBMR.040203 15125799
16. Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. TL Johnson-Pais JH Wisdom KS Weldon JD Cody MF Hansen FR Singer RJ Leach, J Bone Miner Res 2003 18 1748 1753 10.1359/jbmr.2003.18.10.1748 14584883
17. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. GJ Lucas LJ Hocking A Daroszewska T Cundy GC Nicholson JP Walsh WD Fraser C Meier MJ Hooper SH Ralston, J Bone Miner Res 2005 20 227 231 10.1359/JBMR.041106 15647816
18. Goals of treatment for Paget's disease of bone. ES Siris, J Bone Miner Res 1999 14 Suppl 2 49 52 10510214
19. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. IR Reid P Miller K Lyles W Fraser JP Brown Y Saidi P Mesenbrink G Su J Pak K Zelenakas, N Engl J Med 2005 353 898 908 10.1056/NEJMoa044241 16135834
20. A single dose of Zoledronic acid 5 mg achieves more sustained biochemical remission verses daily 30 mg Risedronate in patients with Paget's disease. I Reid P Miller J Brown W Fraser D Hosking JP Devogelaer C Moniz M Hooper Y Saidi G Su, Calcif Tissue Int 2006 78 S39
21. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). HI Harinck SE Papapoulos HJ Blanksma AJ Moolenaar P Vermeij OL Bijvoet, Br Med J (Clin Res Ed) 1987 295 1301 1305 3120987
22. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. PD Miller JP Brown ES Siris MS Hoseyni DW Axelrod PJ Bekker, Am J Med 1999 106 513 520 10.1016/S0002-9343(99)00062-5 10335722
23. Health Behavior. M Connor P Norman, Health Psychology Amsterdam: Elsevier Science Publishers BV, Johnston DW, Johnston M, Bellack AS, Hersen M, 2001 8 1 37 Compehensive Clinical Psychology
24. Efficacy of the Theory of Planned Behaviour: A meta-analytic review. CJ Armitage M Connor, British Journal of Social Psychology 2001 40 471 499 10.1348/014466601164939 11795063
25. Implementation intentions & the theory of planned behaviours. S Orbell S Hodgkins P Sheeran, Personality & Social Psychology Bulletin 1997 23 945 954 10.1177/0146167297239004
26. M Fishbein, Attitude & the predicition of behaviour. Readings in attitude, theory & measurement New York: J Wiley & Sons 1967
27. Reluctance to undergo predictive testing: the case of Huntington disease. KA Quaid M Morris, Am J Med Genet 1993 45 41 45 10.1002/ajmg.1320450112
28. Psychological responses to genetic testing. T Marteau RT Croyle, BMJ 1998 316 693 696 9522800
29. Illness representations and coping with health threats. H Leventhal DR Nerenz DS Steele, Handbook of Psychology and Health Hillsdale, New Jersey: Erlbaum, Baum A, Taylor SE, Singer JE, 1984 227 231
30. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. J Weinman K Petrie R Moss-Morris R Horne, Psychology and Health 1996 11 431 445 10.1080/08870449608400270
31. Applying Leventhal's self regulation model to adaptation and intervention in rheumatic disease. TJ Pimm J Weinman, Clinical Psychology & Psychotherapy 1998 5 62 75 10.1002/(SICI)1099-0879(199806)5:2<62::AID- CPP155〉3.0.CO;2-L
32. The Revised Illness Perception Questionnaire (IPQ-R). R Moss-Morris J Weinman K Petrie R Horne L Cameron D Buick, Psychology and Health 2002 17 1 16 10.1080/08870440290001494
33. The Brief llness Perception Questionnaire. E Broadbent KJ Petrie J Main J Weinman, Journal of Psychosomatic Research 2006 60 631 637 10.1016/j. jpsychores.2005.10.020 16731240
34. WHO International Classification of Functioning, Disability and Health. Geneva: WHO 2004
35. One to be taken as directed: Reflections on non-adherence (non-compliance). R Horne, Journal of Social and Administrative Pharmacy 1993 10 150 156
36. The theory of planned behaviour. I Ajzen, Organizational behavior and Human Decision Processes 1991 50 179 211 10.1016/0749-5978(91)90020-T
37. A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation. W Hardeman S Sutton S Griffin M Johnston A White NJ Wareham AL Kinmonth, Health Educ Res 2005 20 676 687 10.1093/her/cyh022 15781446
38. Two alternative models of health behaviour and recovery from activity limitations due to acute injury: A prospective study. GJ Molloy FF Sniehotta M Johnston, Psychology and Health
39. Protocol for stage 1 of the GaP study (Genetic testing acceptability for Paget's disease of bone): an interview study about genetic testing and preventive treatment: would relatives of people with Paget's disease want testing and treatment if they were available? AL Langston M Johnston C Robertson MK Campbell VA Entwistle TM Marteau M McCallum SH Ralston, BMC Health Serv Res 2006 6 71 16762063 10.1186/1472-6963-6-71
40. http://www-unix.oit.umass.edu/%7Eaizen/
41. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. T Marteau V Senior S Humphries M Bobrow T Cranston M Crook L Day M Fernandez R Horne A Iversen, American Journal of Medical Genetics Part A 2004 128A 285 293 10.1002/ajmg.a.30102 15216550
42. B Tabachnik L Fidell, Using Multivariate Statistics New York: Harper Collins 1996
43. CA Moser G Kalton, Survey methods in social investigation New York: Basic Books 2 1972
44. Consequences of disease: testing the WHO International Classification of Impairments, Disabilities and Handicaps (ICIDH) model. M Johnston B Pollard, Soc Sci Med 2001 53 1261 1273 10.1016/S0277-9536(00)00384-1 11676399
45. What do osteoarthritis health outcome instruments measure? Impairment, activity limitation or participation restriction? B Pollard M Johnston P Dieppe, Journal of Rheumatology 2006 33 16358368
46. Medical Research Council. http://www.mrc.ac.uk
47. National Assocation of the Relief of Paget's Disease. http://www.paget.org.uk